Tysabri (natalizumab) is very effective for people with highly active relapsing remitting MS but it carries the risk of developing a rare but very serious brain infection called progressive multifocal leukoencephalopathy (PML).
Posts with the 2019 tag
Siponimod recommended for secondary progressive MS by EMA
The European Medicines Agency (EMA) has recommended that a licence should be granted for siponimod (Mayzent) for the treatment of active secondary progressive MS (SPMS).
BBC Radio Kent visits the Centre
On 3rd October we were excited to welcome two journalists to the Centre during our monthly Coffee Morning!
Rex Robotic Exoskeleton Trial
East Kent leads the way in robotic trials to improve patients’ mobility. Patients from Scotland, Suffolk, London, Surrey, Essex and Berkshire are travelling to Kent to take part in a ground-breaking clinical trial at the Kent and Canterbury Hospital.
Summer Fete Fundraiser raises over £2,000!
Swanley Therapy Centre held it’s annual Summer Fete fundraiser on the 8th June 2019. The event was a great success raising over £2,000 with over 120 attendees.